MetaCap

Amgen (AMGN) vs BioNTech (BNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amgen (AMGN) has outperformed BioNTech (BNTX) over the past year, gaining 29.1% versus a loss of 15.3%. Over five years, AMGN leads with a +116.6% price change compared with -76.7% for BNTX. Amgen is the larger company by market cap ($235.64 billion vs $20.07 billion), about 11.7 times the size.

Amgen pays a dividend yielding 2.28%, while BioNTech does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMGN+29.06%BNTX-15.30%
+45%+13%-18%
Nov 21, 20251 yearNov 20, 2026
AMGN+111.39%BNTX-72.06%
+136%+27%-82%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMGN versus BNTX key metrics
MetricAMGNBNTX
Share price$435.64$80.96
Market cap$235.64B$20.07B
1-day change-0.15%-0.52%
YTD return+33.10%-14.96%
1-year return+29.06%-15.30%
5-year return+116.64%-76.74%
P/E ratio (TTM)25.25—
Forward P/E17.34—
EPS (TTM)$17.25$-6.83
Dividend yield2.28%0.00%
Annual dividend$9.94$0.00
Revenue (latest FY)$36.75B—
Revenue growth (YoY)+9.95%—
Net income (latest FY)$7.71B—
Gross margin67.25%—
Operating margin24.71%—
Net margin20.98%—
52-week high$483.99$124.00
52-week low$312.39$79.52
Distance from 52-week high-9.99%-34.71%
Analyst consensusholdbuy
Avg. price target upside-0.88%+38.51%
Average volume2.82M1.08M
Shares outstanding540.91M247.93M
Employees31,5007,807
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Amgen is about 11.7 times larger than BioNTech by market value ($235.64B vs $20.07B).
  • AMGN has outperformed BNTX by 44.4 percentage points over the past year.
  • Amgen offers a meaningfully higher dividend yield (2.28% vs 0.00%).

About Amgen

AMGN stock →

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees

About BioNTech

BNTX stock →

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees

AMGN vs BNTX FAQ

Which is bigger, Amgen or BioNTech?

Amgen (AMGN) is larger, with a market capitalization of $235.64B compared with $20.07B for BioNTech (BNTX).

Which stock has performed better over the past year, AMGN or BNTX?

AMGN returned +29.06% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Amgen or BioNTech?

Amgen pays a dividend yielding 2.28%, while BioNTech does not currently pay a regular dividend.

Are Amgen and BioNTech in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons